High-dose rituximab (HD-R) combined with carmustine, cytarabine, etoposide and melphalan (BEAM) and autologous stem cell transplant (ASCT) was effective and tolerable in a single-arm prospective study of relapsed aggressive B-cell non-Hodgkin lymphoma (R-NHL). We performed a randomized phase 2 study comparing HD-R versus standard-dose rituximab (SD-R) in R-NHL. Ninety-three patients were randomized to HD-R (1000 mg/m 2 ) (n = 42) or SD-R (375 mg/m 2 ) (n = 51) administered on post-transplant days +1 and +8, using a Bayesian adaptive algorithm. The 2 treatment arms were balanced in regards to patient demographic and clinical characteristics. At a median follow-up of 7Á92 years, the 5-year diseasefree survival (DFS) and overall survival (OS) were 40% and 48%, respectively. We found no statistically significant differences between HD-R and SD-R in 5-year DFS (36% vs. 43%; P = 0Á205) and OS (43% vs. 52%; P = 0Á392). In multivariate analyses, only disease status before ASCT [residual disease versus complete remission (CR)] (hazard ratio [HR] 1Á79, 95% confidence interval [CI]: 1Á08-2Á95) and number of prior treatments received (>2 vs. ≤2 lines of treatment) (HR 1Á89, 95% CI: 1Á13-3Á18) were associated with worse DFS and OS. Patients who had SCT while in CR or who received ≤2 lines of treatment prior to SCT had better 5-year OS (57% vs. 35%; P = 0Á02 and 54% vs. 30%, P = 0Á001, respectively) in both arms. No differences in engraftments or adverse events were noted in the 2 arms. When combined with BEAM and ASCT in relapsed aggressive B-cell NHL, HD-R provided no DFS or OS advantage over SD-R. In patients who have been exposed to rituximab in the frontline or salvage setting, the addition of rituximab in the peri-transplant setting remains controversial.
Summary
High-dose rituximab (HD-R) combined with carmustine, cytarabine, etoposide and melphalan (BEAM) and autologous stem cell transplant (ASCT) was effective and tolerable in a single-arm prospective study of relapsed aggressive B-cell non-Hodgkin lymphoma (R-NHL). We performed a randomized phase 2 study comparing HD-R versus standard-dose rituximab (SD-R) in R-NHL. Ninety-three patients were randomized to HD-R (1000 mg/m 2 ) (n = 42) or SD-R (375 mg/m 2 ) (n = 51) administered on post-transplant days +1 and +8, using a Bayesian adaptive algorithm. The 2 treatment arms were balanced in regards to patient demographic and clinical characteristics. At a median follow-up of 7Á92 years, the 5-year diseasefree survival (DFS) and overall survival (OS) were 40% and 48%, respectively. We found no statistically significant differences between HD-R and SD-R in 5-year DFS (36% vs. 43%; P = 0Á205) and OS (43% vs. 52%; P = 0Á392). In multivariate analyses, only disease status before ASCT [residual disease versus complete remission (CR)] (hazard ratio [HR] 1Á79, 95% confidence interval [CI] : 1Á08-2Á95) and number of prior treatments received (>2 vs. ≤2 lines of treatment) (HR 1Á89, 95% CI: 1Á13-3Á18) were associated with worse DFS and OS. Patients who had SCT while in CR or who received ≤2 lines of treatment prior to SCT had better 5-year OS (57% vs. 35%; P = 0Á02 and 54% vs. 30%, P = 0Á001, respectively) in both arms. No differences in engraftments or adverse events were noted in the 2 arms. When combined with BEAM and ASCT in relapsed aggressive B-cell NHL, HD-R provided no DFS or OS advantage over SD-R. In patients who have been exposed to rituximab in the frontline or salvage setting, the addition of rituximab in the peri-transplant setting remains controversial.
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High-dose therapy (HDT) and autologous stem-cell transplantation (ASCT) remain the standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) and other aggressive B-cell Non-Hodgkin lymphomas (NHL). In the pre-rituximab era, the Parma Study was first to report the survival advantage of HDT and ASCT compared to conventional chemotherapy (Philip et al, 1995) . However, relapse after ASCT remains the main cause of death (Gisselbrecht et al, 2012) , and there is an unmet need to further explore novel approaches to improve disease control rates after transplant. Several studies incorporated rituximab in the salvage and conditioning regimens prior to ASCT or for maintenance therapy. These studies showed conflicting results when rituximab was added to salvage regimens for relapsed patients who had received rituximab in the initial frontline treatment research paper ª 2017 John Wiley & Sons Ltd British Journal of Haematology, 2017, 178, 561-570 (Feugier et al, 2005; Vellenga et al, 2008; Gisselbrecht et al, 2010 Gisselbrecht et al, , 2012 Mounier et al, 2012; Rovira et al, 2015) . Furthermore, there have been few randomized studies comparing salvage regimens used in the relapse setting, with no regimen shown to be superior (Gisselbrecht et al, 2010; Crump et al, 2014) . There is also limited evidence to support the superiority of any of the commonly used conditioning regimens before ASCT. Carmustine, cytarabine, etoposide and melphalan (BEAM) is the preferred regimen by many institutions, due to similar efficacy and acceptable safety profile (Isidori et al, 2015) .
Little success has been achieved to improve HDT regimens over last 3 decades. None of the conditioning regimens have been compared prospectively in randomized studies, and evidence is mostly based on observational retrospective studies or single arm prospective trials.
High-dose rituximab (HD-R; 1000 mg/m 2 ) in combination with BEAM and ASCT was effective and tolerable in a single-arm prospective study for relapsed/refractory DLBCL and aggressive B-cell NHLs (Khouri et al, 2005) . HD-R was given to all patients (n = 67) on days 1 and 8 post-stem cell infusion. Compared to historical controls (i.e. BEAM alone without rituximab), both overall survival (OS) and diseasefree survival (DFS) rates were significantly improved in the HD-R arm. This report presents long term results from the largest single centre randomized phase 2 clinical trial to date, comparing the efficacy and safety of HD-R versus standard-dose rituximab (SD-R) combined with BEAM in relapsed and refractory B-cell NHLs.
Methods

Study design
This was an open-label prospective, single centre, randomized, phase II study in patients with relapsed/refractory DLBCL or aggressive B-cell NHL comparing two different doses of rituximab combined with high-dose BEAM chemotherapy. The primary endpoint was DFS, defined as time from transplantation to disease relapse/progression or death. OS and safety analysis were secondary endpoints. OS was calculated from time of transplantation to death or last follow-up.
The protocol was approved by the Institutional Review Board of The University of Texas M.D. Anderson Cancer Center. All patients signed an informed consent for the study in accordance with the Declaration of Helsinki. The study was registered at ClinicalTrials.gov (NCT00472056).
Patient eligibility
Patients aged ≤80 years with histologically proven DLBCL, transformed follicular lymphoma or CD20-positive B-cell NHL that had relapsed after conventional chemotherapy were eligible for enrolment. Patients were required to have chemosensitive disease to salvage chemotherapy and less than 5% bone marrow involvement with lymphoma at the time of enrolment. Other eligibility criteria included a Zubrod performance status score of <2 and negative test for pregnancy, human immunodeficiency virus (HIV), hepatitis B surface antigen and hepatitis C antibody. Exclusion criteria were: active central nervous system disease, <3 weeks from last chemotherapy, left ventricular ejection fraction less than 40%, corrected diffusing capacity of the lungs for carbon monoxide (DLCO) <50%, serum creatinine >141Á4 lmol/l, serum bilirubin >25Á65 lmol/l, serum transaminases >2 times upper normal level, and failure to collect more than 2 9 10 6 CD34+ stem cells/kg body weight.
Treatment
Stem cell mobilization. Stem cells were mobilized after the penultimate or final cycle of salvage chemotherapy followed by granulocyte colony-stimulating factor (G-SCF; filgrastim) 6 lg/kg/day (rounded to nearest vial size) or any available mobilization study per investigator choice.
High-dose chemotherapy and stem cell infusion. For patients aged 65 years or younger, BEAM was given in following dosages and schedule: Carmustine 300 mg/m 2 IV over 1 h on day À6, cytarabine 200 mg/m 2 IV twice a day on days À5 to À2 (total 8 doses), etoposide 200 mg/m 2 IV twice a day on days À5 to À2 (total 8 doses) and melphalan 140 mg/m 2 IV on day À1. For patients older than 65 years of age, dose-reduced BEAM was given: Carmustine 300 mg/ m 2 IV over 1 h on day À6, cytarabine 100 mg/m 2 IV twice a day on days À5 to À2 (total 8 doses), etoposide 100 mg/m 2 IV twice a day on days À5 to À2 (total 8 doses) and melphalan 140 mg/m 2 IV on day À1.
For autologous stem cell rescue after HDT, a median of 4Á92 9 10 6 /kg (range 2Á80-25Á01) CD34-positive cells were infused on day 0 of transplant. HD-R 1000 mg/m 2 or SD-R 375 mg/m 2 IV according to randomized arm were given on days +1 and +8 after stem cell infusion. Patients received G-CSF 5 lg/kg/day subcutaneously, beginning on day +1 until haematological recovery. All patients received concomitant supportive care according to established institutional bone marrow transplant guidelines at MD Anderson Cancer Center.
Safety and response assessments
Toxicity grades were based on Common Terminology Criteria for Adverse Events version 3 (CTCAE v 3.0; http://ctep.ca ncer.gov/protocolDevelopment/electronic_applications/docs/ ctcaev3.pdf). All patients underwent the following baseline staging procedures: physical examination, complete blood count with differential count, serum chemistry panel, quantitative immunoglobulins, serum beta2-microglobulin measurement, urine analysis, pregnancy test for patients of child bearing age, bone marrow aspiration and biopsy, review of pathology slides, computed tomography (CT) of the neck, chest, abdomen and pelvis. Gallium scanning and/or positron emission tomography (PET) scan were done as clinically indicated. Re-staging studies included CT scans at day 30 after ASCT, and then at 3 months and 6 months, and thereafter every 6 months for 3 years (unless clinically indicated) and then annually while the patient was on study. Bone marrow biopsy was repeated only if indicated to document remission. If a gallium or PET scan was performed at baseline and was positive, then it was repeated after transplant to confirm remission. Responses were assessed and defined as previously described by Cheson et al (1999) . Haematopoietic engraftment post-transplant recovery was determined by neutrophil count recovery, defined as the first of 3 consecutive days when the absolute neutrophil count was >0Á5 9 10 9 /l, and platelet count recovery defined as the first day after transplantation when the platelet count was >20 9 10 9 /l (independent of platelet transfusions).
Statistical methods
Patients were randomized between the two study arms using a Bayesian adaptive algorithm (Berry & Eick, 1995) . We assumed that DFS for each treatment arm follows the same Weibull distribution, with a parameter for age group (<65, ≥65 years). The prior distributions of the Weibull parameters were chosen so that the median DFS was 26 months for patients younger than 65 years and 14 months for patients aged 65 years and older. The prior distributions were updated with follow-up and event data throughout the trial to obtain posterior distributions of DFS for each treatment, adjusted for age. For each patient the randomization probability for a treatment was the posterior probability that it had longer median DFS than the other treatment. Preplanned sample size was 100 patients; however, the trial was closed to new patient entry by the MD Anderson Data and Safety Monitoring Board (DSMB) after 93 patients had been enrolled because it was considered extremely unlikely that either treatment arm would have statistically superior DFS should the trial enrol the full complement of the originally planned 100 patients. The Kaplan-Meier method was used to estimate the median time to event, including DFS, event-free survival and OS, and 95% CIs were calculated. Cox proportional hazards regression was used to model DFS and OS as a function of treatment while adjusting for age and all significant variables at a P < 0Á15 in univariate analysis, and it was used to calculate the hazard ratios between the two treatment arms. All reported P values are two-sided, and statistical significance was defined as P < 0Á05. The statistical analysis was performed using SAS â software version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Patient clinical characteristics
A total of 93 patients were enrolled in the study period between March 2005 and April 2009 (Fig 1) . Patients were randomly assigned to HD-R (n = 42) or SD-R (n = 51). The median age for the entire group was 63 years (range, 6Á0-75) with male predominance (71% males). A total of 38 (41%) patients were 65 years of age or older, all of whom received dose-reduced BEAM. Baseline patient demographic and clinical characteristics are summarized in Table I . Overall, the two arms were well balanced with no statistically significant differences between the two treatment arms with respect to demographic and clinical characteristics. A total of 53 (57%) patients had relapsed disease from a de novo DLBCL and 40 (43%) had other aggressive B-cell NHLs (Table I ). All patients had prior rituximab exposure, either as frontline and/or with salvage chemotherapy.
Efficacy
The median follow-up of the surviving patients at last follow-up was 7Á92 (range, 3Á76-10Á23) years. The 5-year DFS and 5-year OS for the study group were 40% (95% CI, 29% to 48%) and 48% (95% CI, 37% to 57%), respectively (Fig 2A-B) . There was no statistically significant difference between the HD-R and SD-R arms in 5-year DFS (36% vs. 43%, respectively; P = 0Á205) (Fig 2C) . Similarly, there was no statistically significant difference in the 5-year OS between the HD-R and SD-R arms (43% vs. 52%; P = 0Á392) (Fig 2D) . Among patients aged <65 years, the 5-year DFS and OS were 45% and 53%, respectively, compared to 32% (P = 0Á113) and 42% (P = 0Á039) for those aged 65 years or older. There was no benefit from HD-R treatment in either age group ( Figure S1 ). Univariate and multivariate analysis were performed to identify potential prognostic factors (Table II) . The following were examined in univariate analysis: age group, gender, histology, stage, lactate dehydrogenase (LDH), number of prior lines of treatment, disease status prior to transplant, time from diagnosis to transplant and treatment arm. Five-year DFS and OS were affected primarily by disease status before ASCT (remission versus no remission) and number of prior lines of treatments received (≤2 vs. >2 lines of treatment). Patients who were transplanted while in CR compared to no CR had better 5-year DFS (50% vs. 30%, respectively; P = 0Á026) and OS (57% vs. 35%, respectively; P = 0Á02) (Fig 3A-B) . Similarly, those who received ≤2 lines of treatment prior to ASCT compared to >2 lines had significantly better 5-year DFS (45% vs. 30%, respectively; P = 0Á006) and OS (54% vs. 30%, respectively; P = 0Á001) (Fig 3C-D) . In the Cox model, patients who had HDC and ASCT while having partial response or stable disease had significantly worse Subgroup analyses were performed (by age, gender, LDH, histology, disease status prior to transplant, number of prior lines of treatment) to identify any susceptible subgroups that may benefit from HD-R. None of the subgroups benefited from HD-R (results are not shown). For patients with de novo DLBCL (n = 53), there was no significant difference in DFS and OS by treatment arm. The 5-year DFS for HD-R and SD-R was 35% and 48%, respectively (P = 0Á382), and the 5-year OS rates were 39% and 52% (P = 0Á443), respectively ( Figure S2 ). Among patients with de novo DLBCL, only 31 patients had their cell of origin pathological subtype determined by Hans' algorithm (Hans et al, 2004) ; 26 were germinal centre B-cell (GCB) and 5 were non-GCB type. For the patients with GCB type, we didn't find any statistically significant differences in survival outcomes by treatment arm.
Engraftment
A median of 5Á25 (range 2Á95-15Á38) and 4Á88 (range 2Á80-25Á01) million/kg CD34-postive cells were infused in the HD-R and SD-R study groups, respectively. There were no statistically significant differences in engraftment times between the 2 treatment arms. The median time to ANC engraftment (≥0Á5 9 10 9 /l) was 10 (8-12) days for HD-R and 10 (9-17) days for SD-R. The median time for platelet recovery (≥20 9 10 9 /l) was 11 (7-42) days for HD-R and 10 (6-106) days for SD-R.
Safety
The adverse event profile was similar in the two arms. Grade 3-4 toxicities are listed in Table III ; a total of 12 grade 3-4 adverse events occurred among 40 patients in the HD-R arm and 13 events in the SD-R arm. Infection rates were similar between both arms. At the time of last follow-up, a total of 58 deaths (62%) had occurred, 28 in the HD-R arm and 30 in the SD-R arm, with the majority of deaths due to lymphoma recurrence (30 patients, 15 in each arm) (Table IV) . Eleven patients died of second primary malignancy (SPM) and 7 patients died of infection (Table IV) . Only one death occurred within 100 days after ASCT in the HD-R arm, and death was attributed to infection and persistent disease.
Second primary malignancy
After a median follow up of 7Á9 years, 18 patients had developed SPM, 8 in the HD-R group and 10 in the SD-R group. The median time to SPM diagnosis was 68 months (range, 16-175 months) from diagnosis date and 33 months (range, 2-69 months) from transplant date. Eight patients had haematological secondary neoplasm (6 in the HD-R arm), 9 patients had second solid neoplasms (2 in the HD-R), and 1 patient in the SD-R arm developed both myelodysplastic syndrome and lung cancer. A total of 11 deaths were attributed to SPM (6 secondary to haematological neoplasms), with no apparent differential contribution by study arm (Table IV) .
Discussion
This report presents the long term outcomes of the randomized single centre clinical trial to comparing HD-R versus SD-R combined with BEAM in patients with relapsed DLBCL and aggressive transformed B-cell NHLs. After a median follow-up of 7Á9 years, the results demonstrated similar short-term and long-term outcomes in regards to DFS, OS and adverse events in the two treatment groups. Subgroup analysis including age (<65 years vs. ≥65 years), gender, histology, pre-transplant disease status and number of prior lines of treatment didn't identify any subset that could benefit from HD-R. Disease status before transplant (CR/CRu) and number of prior treatments (≤2 prior treatments) were the only variables to predict an improved outcome with transplantation.
The introduction of rituximab in management of B-cell lymphomas has improved treatment outcomes; however, as rituximab is universally used in the frontline setting in the CR, complete remission; CRu, complete remission unconfirmed; DLBCL, diffuse large B-cell lymphoma; HR, hazard ratio; IPI, International Prognostic Index; NHL, non-Hodgkin lymphoma; PR, partial response; SD, stable disease. *All patients were in partial remission except for 3 patients in the standard-dose rituximab arm and 2 patients in the high-dose arm.
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ª 2017 John Wiley & Sons Ltd current era, its role has been questioned when used in combination with salvage therapy in the relapsed setting (Martin et al, 2008; Gisselbrecht et al, 2010) . Rituximab has been used safely in the pre-and post-transplant setting without adverse effects on stem cell mobilization, engraftment, transplant-related toxicities and mortality, and deemed potentially effective (Magni et al, 2000; Horwitz et al, 2004; Kamezaki et al, 2007; Tarella et al, 2008 Tarella et al, , 2011 . It has been hypothesized that pre-transplant rituximab may enhance antitumour effects by sensitizing specific effector cells and modulating immune reconstitution associated with transplant (Fenske et al, 2009 ). In the peri-transplant setting, it has been suggested that rituximab may reduce tumour-cell contamination and improve molecular remission (Brugger et al, 2004; Khouri et al, 2005) , which may lead to decreased relapse after transplant. Our results seem less favourable compared to our prior nonrandomized prospective trial investigating the role of HD-R combined with BEAM in relapsed aggressive B-Cell lymphomas (Khouri et al, 2005) ; rituximab was also given to all patients during chemomobilzation, 1 day before (at 375 mg/m 2 ) and 7 days after chemotherapy (1000 mg/m 2 ).
With a shorter median follow up of 20 months, the earlier study (Khouri et al, 2005) showed impressive 2-year DFS and OS of 67% and 80%, respectively, for patients who received HD-R compared to 43% and 53%, respectively, for historical controls without rituximab. An updated analysis was presented recently in abstract form after a median follow-up of 11Á8 years, showing a 5-year DFS and OS of 62% and 74%, respectively, for patients treated with HD-R (Khouri et al, 2015) . The findings from our randomized trial failed to confirm a dose-response effect of rituximab and demonstrate a benefit of HD-R compared to SD-R and to reproduce the aforementioned results. The fact that all patients in the prior nonrandomized trial had not received rituximab as part of their frontline therapy probably accounts for the different results between that trial and the present one in a more modern patient population.
Additionally, in the study reported by Khouri et al (2005) all patients received HD-R 7 days after chemomobilization, in contrast to current trial where there was heterogeneity in chemomobilization regimens chosen per investigator discretion and not all patients received HD-R after chemomobilization. The inferior outcomes in our study for peritransplant rituximab compared to the earlier more favourable results in rituximab-na€ ıve patients (Khouri et al, 2005) further highlight the limited role of rituximab in the current era where almost all relapsed patients have been exposed to rituximab with frontline and/or salvage chemotherapy. This is in line with other reports questioning role of rituximab during salvage chemotherapy or in the post-transplant setting in previously exposed patients (Martin et al, 2008; Gisselbrecht et al, 2010 Gisselbrecht et al, , 2012 . Several prognostic factors were analysed to examine their influence on treatment outcomes and to identify any susceptible groups that might benefit from HD-R. On univariate analysis, there was a statistically significant improvement in survival for patients <65 years, however the significance was lost in the multivariate analysis. The only variables predictive for an improved DFS and OS after transplantation were disease status before SCT and number of prior lines of treatment; this is consistent with other reports . Patients who underwent SCT while in CR/CRu and those who had ≤2 lines of prior treatments had the best outcomes. In accordance with other reports (Khouri et al, 2005; Kuruvilla et al, 2015) , univariate and multivariate analyses revealed similar outcomes for relapsed de novo DLBCL and transformed B-cell NHLs.
The safety profile was similar between both study arms. Specifically, there were no increase grade 3-4 infections or treatment-related mortality with HD-R. Likewise, there was no difference in rates of neutrophil and platelet engraftments. The most common cause of death in both study arms was disease relapse; this, along with the aforementioned findings (disease status at transplant and number of prior therapies were predictive for outcomes) highlight the importance of improving salvage regimens to produce better responses prior to SCT, and the need for early referral for transplant. Incorporation of novel agents into salvage regimens and the recent introduction of cellular therapy into management of relapsed Acute respiratory failure * 1 (2) 1 (1) Atrial fibrillation * 2 (5) 2 (2) Bilirubin 1 (2) * 1 (1) Confusion * 1 (2) 1 (1) Congestive heart failure * 1 (2) 1 (1) Deep vein thrombosis * 1 (2) 1 (1) Diarrhoea 3 (6) 1 (2) 4 (4) Dyspnea 1 (2) * 1 (1) Fever 1 (2) * 1 (1) Hypercalcaemia 1 (2) * 1 (1) Infection * 1 (2) 1 (1) Lethargy 1 (2) * 1 (1) Mucositis 1 (2) 2 (5) 3 (3) Nausea * 1 (2) 1 (1) Neuropathic pain * 1 (2) 1 (1) Neutropenic fever 6 (12) 3 (7) 9 (10) Intestinal obstruction * 1 (2) 1 (1) Elevated Alanine Aminotransferase 2 (4) * 2 (2) Skin rash * 1 (2) 1 (1)
*No reported grade 3-4 toxicity. n, number of deaths per study arm; %, percentage of deaths per total per study arm. *For the unknown causes of death, the primary cause of death was not documented. However, one patient in the standard-rituximab group and two patients in the high-dose rituximab group had progressive disease at time of death; all others had no evidence of disease. aggressive B-cell lymphomas are very promising investigational areas for potential improvement in transplantation outcomes. In summary, high-dose rituximab was well tolerated; however, we found no statistically significant differences between HD-R and SD-R when combined with BEAM in relapsed BCell aggressive NHLs in terms of DFS and OS. For patients who had been previously exposed to rituximab, there remains limited evidence to support routine use of rituximab in the peri-transplant setting. Pre-transplant disease status and numbers of treatments prior to transplant were identified as the only significant predictors for prognosis.
